<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807959</url>
  </required_header>
  <id_info>
    <org_study_id>2016-443A</org_study_id>
    <nct_id>NCT04807959</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program</brief_title>
  <official_title>A Retrospective Study to Evaluate the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>20Lighter</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>20Lighter</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective review of body composition outcomes of participants of a comprehensive&#xD;
      visceral-fat focused anti-obesity program. Data from approximately 2000-2500 participants are&#xD;
      expected to be included in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective, multi-center clinical study to evaluate the efficacy of the&#xD;
      20Lighter comprehensive anti-obesity program in reducing body composition measures including&#xD;
      body weight, body fat, visceral adiposity, intracellular fluid, and other metrics of&#xD;
      interest. Anecdotal evidence on reductions of prescription medication, chronic health issues,&#xD;
      and improvements in quality of life will be gauged via review of patient assessment forms and&#xD;
      surveys.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Actual">October 9, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Visceral Adiposity</measure>
    <time_frame>Change from baseline to program completion (60 Days)</time_frame>
    <description>% reduction of visceral adiposity (as measured by visceral fat rating) measured via an FDA-cleared Class 2 medical device with Bioelectrical Impedance Analysis (BIA) via bipolar foot electrodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of Body Weight</measure>
    <time_frame>Change from baseline to program completion (60 Days)</time_frame>
    <description>% reduction of body weight measured via an FDA-cleared Class 2 medical device with Bioelectrical Impedance Analysis (BIA) via bipolar foot electrodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Body Mass Index</measure>
    <time_frame>Change from baseline to program completion (60 Days)</time_frame>
    <description>% reduction of body mass index measured via an FDA-cleared Class 2 medical device with Bioelectrical Impedance Analysis (BIA) via bipolar foot electrodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Body Fat</measure>
    <time_frame>Change from baseline to program completion (60 Days)</time_frame>
    <description>% reduction of body fat measured via an FDA-cleared Class 2 medical device with Bioelectrical Impedance Analysis (BIA) via bipolar foot electrodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of Intracellular Fluid</measure>
    <time_frame>Change from baseline to program completion (60 Days)</time_frame>
    <description>% increase of intracellular fluid (as measured by body water %) measured via an FDA-cleared Class 2 medical device with Bioelectrical Impedance Analysis (BIA) via bipolar foot electrodes.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2200</enrollment>
  <condition>Obesity</condition>
  <condition>Obesity, Morbid</condition>
  <condition>Obesity, Visceral</condition>
  <condition>Central Obesity</condition>
  <condition>Metabolic Disease</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Visceral Obesity</condition>
  <arm_group>
    <arm_group_label>20Lighter Program Participants</arm_group_label>
    <description>All enrolled subjects will have completed a 20Lighter anti-obesity program prior to enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>20Lighter anti-obesity program</intervention_name>
    <description>A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.</description>
    <arm_group_label>20Lighter Program Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults over the age of 18 with overweight or obesity, and may have other comoribid&#xD;
        conditions including hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease&#xD;
        (CVD), nonalcoholic fatty liver disease, sleep apnea, and other related health issues.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &gt;25&#xD;
&#xD;
          -  ability to stand on platform for body composition analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant at time of enrollment&#xD;
&#xD;
          -  Breastfeeding at time of enrollment&#xD;
&#xD;
          -  Undergoing treatment for cancer at time of enrollment&#xD;
&#xD;
          -  History of major organ transplant with immunosuppressant medication&#xD;
&#xD;
          -  Over the 70 years of age with diagnosis of three cardiovascular comorbidities at time&#xD;
             of enrollment&#xD;
&#xD;
          -  Adult with a vegetarian diet&#xD;
&#xD;
          -  Diagnosis of psychiatric conditions including: schizophrenia, bipolar disorder, manic&#xD;
             depression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Barnes, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>20Lighter</affiliation>
  </overall_official>
  <reference>
    <citation>Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA. 2016 Jun 7;315(21):2284-91. doi: 10.1001/jama.2016.6458.</citation>
    <PMID>27272580</PMID>
  </reference>
  <reference>
    <citation>Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, Jordan HS, Kendall KA, Lux LJ, Mentor-Marcel R, Morgan LC, Trisolini MG, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014 Jun 24;129(25 Suppl 2):S102-38. doi: 10.1161/01.cir.0000437739.71477.ee. Epub 2013 Nov 12. Erratum in: Circulation. 2014 Jun 24;129(25 Suppl 2):S139-40.</citation>
    <PMID>24222017</PMID>
  </reference>
  <reference>
    <citation>Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998 Sep;6 Suppl 2:51S-209S. Review. Erratum in: Obes Res 1998 Nov;6(6):464.</citation>
    <PMID>9813653</PMID>
  </reference>
  <reference>
    <citation>Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001 Nov;74(5):579-84.</citation>
    <PMID>11684524</PMID>
  </reference>
  <reference>
    <citation>Balasubramanian P, Longo VD. Growth factors, aging and age-related diseases. Growth Horm IGF Res. 2016 Jun;28:66-8. doi: 10.1016/j.ghir.2016.01.001. Epub 2016 Jan 7.</citation>
    <PMID>26883276</PMID>
  </reference>
  <reference>
    <citation>Barnosky AR, Hoddy KK, Unterman TG, Varady KA. Intermittent fasting vs daily calorie restriction for type 2 diabetes prevention: a review of human findings. Transl Res. 2014 Oct;164(4):302-11. doi: 10.1016/j.trsl.2014.05.013. Epub 2014 Jun 12. Review.</citation>
    <PMID>24993615</PMID>
  </reference>
  <reference>
    <citation>Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Varady KA. Alternate day fasting and endurance exercise combine to reduce body weight and favorably alter plasma lipids in obese humans. Obesity (Silver Spring). 2013 Jul;21(7):1370-9. doi: 10.1002/oby.20353. Epub 2013 May 29.</citation>
    <PMID>23408502</PMID>
  </reference>
  <reference>
    <citation>Collier R. Intermittent fasting: the science of going without. CMAJ. 2013 Jun 11;185(9):E363-4. doi: 10.1503/cmaj.109-4451. Epub 2013 Apr 8.</citation>
    <PMID>23569168</PMID>
  </reference>
  <reference>
    <citation>Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng CW, Cacciottolo M, Martin-Montalvo A, de Cabo R, Wei M, Morgan TE, Longo VD. Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell. 2016 Jul 11;30(1):136-146. doi: 10.1016/j.ccell.2016.06.005.</citation>
    <PMID>27411588</PMID>
  </reference>
  <reference>
    <citation>Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016 Jun 10;16:360. doi: 10.1186/s12885-016-2370-6.</citation>
    <PMID>27282289</PMID>
  </reference>
  <reference>
    <citation>Eshghinia S, Mohammadzadeh F. The effects of modified alternate-day fasting diet on weight loss and CAD risk factors in overweight and obese women. J Diabetes Metab Disord. 2013 Jan 9;12(1):4. doi: 10.1186/2251-6581-12-4.</citation>
    <PMID>23497604</PMID>
  </reference>
  <reference>
    <citation>Hoddy KK, Kroeger CM, Trepanowski JF, Barnosky A, Bhutani S, Varady KA. Meal timing during alternate day fasting: Impact on body weight and cardiovascular disease risk in obese adults. Obesity (Silver Spring). 2014 Dec;22(12):2524-31. doi: 10.1002/oby.20909. Epub 2014 Sep 24. Erratum in: Obesity (Silver Spring). 2015 Apr;23(4):914.</citation>
    <PMID>25251676</PMID>
  </reference>
  <reference>
    <citation>Longo VD, Panda S. Fasting, Circadian Rhythms, and Time-Restricted Feeding in Healthy Lifespan. Cell Metab. 2016 Jun 14;23(6):1048-1059. doi: 10.1016/j.cmet.2016.06.001. Review.</citation>
    <PMID>27304506</PMID>
  </reference>
  <reference>
    <citation>Mattson MP, Allison DB, Fontana L, Harvie M, Longo VD, Malaisse WJ, Mosley M, Notterpek L, Ravussin E, Scheer FA, Seyfried TN, Varady KA, Panda S. Meal frequency and timing in health and disease. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16647-53. doi: 10.1073/pnas.1413965111. Epub 2014 Nov 17.</citation>
    <PMID>25404320</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

